Pharmaceuticals News and Research

RSS

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

ValueRich commences litigation against China Pharmaceuticals

ValueRich, Inc. announced today that the company has commenced litigation against China Pharmaceuticals, a publicly traded company under the symbol for breach of contract and other related claims. ValueRich alleges ownership of 20% of the outstanding shares of China Pharmaceuticals "pursuant to a May 2009 Consulting Agreement between ValueRich and Xian Pharmaceuticals, Ltd, the Chinese-based operating company for China Pharmaceuticals."

17 Jun 2010

USPTO issues patent covering Probuphine for opiate addiction

Titan Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued patent number 7,736,665 covering Probuphine for the treatment of opiate addiction.

16 Jun 2010

PRA International Clinical Research Organization opens Phase I facility in Budapest

PRA International, a leading Clinical Research Organization, announces the opening of a Phase I facility in Budapest, Hungary that will provide "unit-on-demand" service and further enhance PRA's capabilities for conducting early-development trials in patients.

16 Jun 2010

Soligenix signs common stock purchase agreements with existing and new investors

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that it has entered into common stock purchase agreements with both existing and new investors totaling approximately $5.16 million. Soligenix's North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this financing.

16 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

Brazilian breast cancer drug market to grow from $424M in 2009 to $611M in 2014: Decision Resources

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the breast cancer drug market in Brazil will grow from $424 million in 2009 to $611 million in 2014. Factors promoting the market's growth include steady increases in the number of incident breast cancer cases, shifts toward higher-cost chemotherapy and hormonal regimens in the adjuvant setting and increases in the use of targeted therapies following novel product launches and label extensions.

16 Jun 2010

Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

16 Jun 2010

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that a phase 2a study of NU1618, the company's lead program, met its primary endpoint of reduction in serum uric acid (sUA) levels in patients with hyperuricemia.

16 Jun 2010

Report reveals increase in patients influence on success, failure of new drugs

Patients are emerging as an increasingly strong group when it comes to influencing the success and failure of new drugs - according to a newly published New Health Report commissioned by Quintiles to gauge the opinions of biopharma executives, managed care executives and patients, and to track progress in the New Health.

16 Jun 2010

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the issuance of U.S. Patent Nos. 7,615,353, which issued in November 2009, and 7,736,861, which issued yesterday.

16 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.

16 Jun 2010

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

For the first time, Sweden-based Biovator AB and its cooperation partners will reveal the crucial aspects of the company's unique, animal-free testing method for human-specifi c allergenicity. A detailed presentation is being created for participants in the 2010 ICCA-LRI & JRC Workshop (International Council of Chemical Associations Long-Range Research Initiative), which will take place June 16-17, 2010 at the Grand Hotel Bristol in Stresa, Italy.

16 Jun 2010

Senior U.S. healthcare executives divided over healthcare reform: Survey

With their world turned upside down by enactment of healthcare reform, senior U.S. healthcare executives are divided over whether the new environment offers growth possibilities or challenges to the survival of existing business models, a new survey shows.

16 Jun 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance the study of cell biology, stem cell research, biopharmaceutical production, and drug discovery, has entered into an agreement with the Salk Institute for Biological Studies to provide its researchers with the LEAP™ Cell Processing Workstation.

16 Jun 2010

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London. The study's principal investigators were Drs. Eric Bateman, Mary Bateman and Paul Potter.

16 Jun 2010

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that the European Commission has granted Orphan Medicinal Product Designation for QPI-1002 (also referred to as "I5NP") for the prophylaxis of delayed graft function in kidney transplant patients.

16 Jun 2010

Pharmaceuticals News and Research

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

ValueRich commences litigation against China Pharmaceuticals

USPTO issues patent covering Probuphine for opiate addiction

PRA International Clinical Research Organization opens Phase I facility in Budapest

Soligenix signs common stock purchase agreements with existing and new investors

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

Brazilian breast cancer drug market to grow from $424M in 2009 to $611M in 2014: Decision Resources

Life Technologies forms GIBCO Cell Therapy Systems

Nuon Therapeutics NU1618 phase 2a study in hyperuricemia meets primary endpoint

Report reveals increase in patients influence on success, failure of new drugs

AVEO granted patents for tests to identify cancer patients likely to respond to tivozanib

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

Norgine to develop and commercialize Tranzyme's ulimorelin ghrelin agonist

Animal-free testing method for human-specific allergenicity displayed at 2010 ICCA-LRI & JRC Workshop

Senior U.S. healthcare executives divided over healthcare reform: Survey

Nymox near completion of new NX-1207 follow-up study for BPH

Cyntellect to provide LEAP Cell Processing Workstation to Salk Institute for Biological Studies

Results from ICH compliant Phase II study of MRX-4 presented at EAACI Congress

European Commission grants Orphan Medicinal Product Designation for QPI-1002

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence